Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
Trial Parameters
Brief Summary
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.
Eligibility Criteria
Inclusion Criteria: * Clinically diagnosed with androgenetic alopecia (AGA) * No pregnancy plans within the next 6 months Exclusion Criteria: * Patients who received systemic medications for hair loss within the past 2 months * Use of topical medication for hair loss within the past 2 weeks * Pregnancy or lactation * Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.